Nephros reported strong revenue growth of 33% and improved net income and adjusted EBITDA, despite challenges like tariff impacts and increased R&D and SG&A expenses. The company's expansion into new markets and strong customer retention are promising. However, the Q&A section revealed some vagueness in management's responses, which could be a concern. Overall, the strong financial performance and strategic growth initiatives outweigh the negatives, suggesting a positive stock price movement.